Therapeutic category of drugs in Japan [BR:br08301]
4 Agents affecting cellular function
42 Antineoplastics
429 Miscellaneous
4291 Other Antitumors
D12364 Taletrectinib adipate (JAN/USAN)
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03226 Taletrectinib
D12364 Taletrectinib adipate
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03226 Taletrectinib
D12364 Taletrectinib adipate
DG01642 CYP2C9 substrate
DG03226 Taletrectinib
D12364 Taletrectinib adipate
DG01633 CYP3A/CYP3A4 substrate
DG03226 Taletrectinib
D12364 Taletrectinib adipate
Target-based classification of drugs [BR:br08310]
Protein kinases
Receptor tyrosine kinases (RTK)
INSR family
ROS1
D12364 Taletrectinib adipate (JAN/USAN) <US>
TRK family
NTRK
D12364 Taletrectinib adipate (JAN/USAN) <US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D12364
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D12364
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D12364
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D12364
Pharmacogenomic biomarkers [br08341.html]
Somatic variations in targeted cancer therapies
D12364
Drug groups [BR:br08330]
Antineoplastic
DG01918 Tyrosine kinase inhibitor
DG03226 Taletrectinib
Metabolizing enzyme substrate
DG02918 CYP2C8 substrate
DG03226 Taletrectinib
DG01642 CYP2C9 substrate
DG03226 Taletrectinib
DG01633 CYP3A/CYP3A4 substrate
DG03226 Taletrectinib